CTLA-4

dart board miss failure
Favicon Fierce Pharma

Merck's Welireg surprisingly fails in first-line kidney cancer

Welireg's phase 3 flop in first-line kidney cancer comes as a surprise following two late-stage trial wins in the second-line and adjuvant settings.
Angus Liu Apr 21, 2026 10:00am
Abstract arrangement of geometric shapes including spheres a pyramid and balancing wooden and stone slabs

BioNTech's CTLA-4 drug improves survival in phase 3 cancer trial

Dec 8, 2025 7:47am
Deal terminate tear up end deal scrap

UroGen hands CTLA-4 drug back to Agenus after mulling ph. 1 data

Nov 6, 2025 10:00am
pipeline new drugs pipes faucet

Instil refills pipeline in $2B biobucks deal with ImmuneOnco

Aug 1, 2024 10:19am
cuts cut

BMS exits next-gen Yervoy pact, taking $300M in biobucks with it

Mar 12, 2024 7:07am
graphic image of stick figures being pushed out of a line indicating theyre being removed or fired

Agenus lays off 25%, sidelines programs to focus on cancer combo

Aug 23, 2023 11:04am